Ukraine, represented by Minister of Health Maxim Stepanov, has agreed to conduct future clinical trials in the country of a “nasal” candidate vaccine from the Indian company Bharat Biotech. The head of the Ministry of Health announced this at a briefing after returning from a trip to India.
“During the negotiations, we agreed on the readiness of Ukraine to participate in clinical trials of a new development, a new vaccine, which they produced in the form of a nasal spray or drops,” he said.
The drug was developed using the adenoviral vector technology: the same as Oxford / AstraZeneca, Sputnik-5 and others.
See also: Vaccine for Ukraine. Hospital admissions plummeted after AstraZeneca dose: UK data
ВBV154 is a drug in which a section of the coronavirus genome encoding the production of S-protein, the main irritant for the immune system, is “sewn” into the genome of a chimpanzee adenovirus (which serotype is not reported), which is completely harmless to humans. When such a GMO-adenovirus enters the body, the cells begin to produce S-protein, on which immunity is immediately “trained”. When they then meet with a real coronavirus, the body will already have an established scheme of protection against the disease.
The news is supplemented …
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
